RP-HPLC Method Development and Validation of Ebastine in Bulk and Injectable Dosage Form

Clicks: 4
ID: 309153
2025
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #90 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The current study presents the development and validation of a novel reverse-phase high-performance liquid chromatography (RP-HPLC) method for the quantification of Ebastine in injectable formulations. A comprehensive literature review revealed the absence of reported RP-HPLC methods for the determination of Ebastine in this dosage form. The method was developed using an InertSustain AQ-C18 column (150 × 4.6 mm, 5 µm) and a mobile phase comprising a pH 5.5 buffer and acetonitrile in a 30:70 (% v/v) ratio. The mobile phase was pumped at a flow rate of 2.0 mL/min, and detection was carried out at 255 nm using a PDA detector. Ebastine exhibited a distinct retention time at 4.072 minutes. The method was validated in accordance with ICH guidelines for parameters including system suitability, specificity, linearity, accuracy, precision, robustness, and filter validation. Results demonstrated excellent linearity (R² = 0.9998), high recovery (100.4%), and satisfactory system suitability with %RSD of 0.041, a symmetry factor of 0.94, and 6029 theoretical plates. Specificity studies confirmed no interference from diluent, placebo, or degradation products. The method was robust and filter validation indicated minimal assay variability among different filter types. The developed method is accurate, precise, rapid, and cost-effective, making it suitable for routine quality control analysis of Ebastine in injectable dosage forms.
Reference Key
imported_1761926391_6904dcf7501ef Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Y. Prapurnachandra
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2025
DOI
10.62896/ijpdd.2.5.01
URL
https://ijpdd.org/index.php/files/article/view/264
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.